

ondine



For Immediate Release

**Ondine Announces Periowave™ Photodisinfection Data Published in
The Journal of Clinical Dentistry®**

Vancouver, Canada – April 2, 2007 - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced the publication of a peer-reviewed research paper in the April 2007 issue of *Journal of Clinical Dentistry* entitled, “Treatment of Periodontal Disease by Photodisinfection Compared to Scaling and Root Planing”. In this randomized and controlled study, the authors reported that the Periowave™ photodisinfection system improved the clinical attachment level by 239% at 12 weeks over the standard approach of scaling and root planing alone (p=0.02). The study was conducted by clinicians at a group practice located in Everett, Washington.

The objective of the Everett trial was to examine the efficacy and safety of Periowave™ in patients with moderate to severe adult periodontitis. The trial included 33 patients between the ages of 18-75 years of age in a suburban Seattle/Everett population. There were a total of 622 treatment sites that were treated and followed for 12 weeks. The primary outcome of the trial was to assess the difference between patients treated with Periowave™ plus scaling and root planing to those treated with scaling and root planing alone.

In addition to the statistically significant improvement in clinical attachment level, in 33% of treated subjects, Periowave™ therapy resulted in average pocket depth reductions exceeding 1.5 mm. None of the subjects in the scaling and root planing alone group experienced recoveries of this magnitude.

“The data presented in this paper further validates our belief that Periowave™ will become part of the standard of care for the treatment of periodontal disease”, said Carolyn Cross, President and CEO of Ondine Biopharma. “We will continue to evaluate Periowave™ under different conditions of clinical use, for extended follow-up periods and for other oral infections and applications.”

About Periowave™ and Photodisinfection (PDD)

Periowave™ is a Photodisinfection system developed by Ondine that utilizes low-intensity lasers and wavelength-specific, light-activated compounds to specifically target and destroy microbial pathogens and reduce the symptoms of disease. The compounds are generally topically applied and one or more lasers are used to activate the compounds and complete the disinfection. The Photodisinfection technologies were developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business PLC, University College London. Additional information about Periowave™ is available at www.periowave.com.

About Ondine Biopharma Corporation:

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading-edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.

The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Redmond, Washington, USA, a sales and marketing subsidiary in York, Pennsylvania, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.

For further information please contact:

Carolyn Cross	Christina Bessant
President and Chief Executive Officer	Investor Relations
Ondine Biopharma Corporation	The Equicom Group Inc.
(604) 669-0555	(416) 815-0700 ext. 269
ccross@ondinebiopharma.com	cbessant@equicomgroup.com